Kratom Toxicity Review: Opioid-Like Symptoms, Organ Risks, and Variable Naloxone Response

Why it matters

As kratom-related emergency department visits increase alongside the DEA's 2026 scheduling actions, clinicians need a current evidence base for recognizing and managing kratom toxicity. This review synthesizes available case reports and mechanistic data to guide clinical decision-making.

The big picture

Kratom's dual pharmacological profile — stimulant at low doses, opioid-like at higher doses — complicates emergency management. The partial mu-opioid receptor agonism of mitragynine and the more potent activity of 7-HMG create toxicity presentations that may resemble opioid overdose but respond inconsistently to standard reversal agents. With kratom use affecting an estimated 16 million Americans and state-level bans driving users toward unknown alternatives, clinicians increasingly need kratom toxicology training.

Key findings

• Kratom toxicity presents as an opioid-like toxidrome in acute overdose, with respiratory depression, sedation, and altered mental status
• Naloxone responsiveness is variable — some cases respond partially or incompletely, unlike classic opioid overdoses
• Multiple organ systems are at risk, including the liver, kidneys, lungs, and cardiovascular system
• Hepatotoxicity, seizures, and coma have been reported in case series
• High-dose and prolonged use dramatically increases risk compared to traditional low-dose consumption
• Concomitant use with other substances, especially other opioids, amplifies toxic risk significantly

What they say

The authors note that "kratom-associated toxicity can produce opioid-like toxidromes with variable responsiveness to naloxone," recommending clinicians maintain heightened vigilance and be prepared for escalating supportive care.

Bottom line

Kratom overdose mimics opioid toxicity but may not fully reverse with naloxone — clinicians treating suspected kratom poisoning must prepare for prolonged supportive care and multi-organ monitoring.